ASAthanasia Stoupa

Athanasia Stoupa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Athanasia Stoupa has a total of 319 co-authors. Here are the top co-authors by number of shared publications:

  • Michel Polak

    10 shared publications
  • Dulanjalee Kariyawasam

    Service d'Endocrinologie, Diabétologie, Gynécologie Pédiatriques, Hôpital Necker-Enfants Malades, AP-HP Centre Université de Paris Cité, Paris, France

    9 shared publications
  • Aurore Carré

    Université Paris Cité, CNRS, Inserm, UMR-S 1016, Institut Cochin , F-75014 Paris

    7 shared publications
  • Adrien Nguyen Quoc

    Université Paris Cité, CNRS, Inserm, UMR-S 1016, Institut Cochin , F-75014 Paris

    5 shared publications
  • Caroline Thalassinos

    Pediatric Endocrinology, Diabetology and Gynecology Department Necker Children's University Hospital, Assistance Publique Hôpitaux de Paris‐APHP, ENDO‐ERN (European Reference Network) Center for Rare Endocrine Diseases Paris France

    5 shared publications
  • Isabelle Flechtner

    Pediatric Endocrinology, Diabetology and Gynecology Department Necker Children's University Hospital, Assistance Publique Hôpitaux de Paris‐APHP, ENDO‐ERN (European Reference Network) Center for Rare Endocrine Diseases Paris France

    5 shared publications

Latest Publications

  • Open Access

    Effects of T3 analogue Triac on caregiver-reported patient-centered outcome measures in patients with MCT8 deficiency: post-hoc analysis of an international, phase 2 trial

    by Matthijs E.T. Freund, Floor van der Most, Ferdy S. van Geest, Robin P. Peeters, Carla Moran, Athanasia Stoupa, Françoise Auriol, Davide Tonduti, Alice Dica, Laura Paone, et al.

  • Open Access

    Clinical, Radiologic and Cytologic Predictors of Malignancy in Pediatric Thyroid Nodules: Insights From a 26‐Year Cohort Study

    by Maxime Gest‐Laurent, Adrien Nguyen Quoc, Christine Lefevre, Laura González‐Briceño, Caroline Thalassinos, Isabelle Flechtner, Dulanjalee Kariyawasam, Yamina Dassa, Magali Viaud, Dinane Samara‐Boustani, et al.

    Introduction: Thyroid nodules are less common but more often malignant in pediatric patients than in adults. Our objectives were to study the features of benign vs. malignant thyroid nodules in a large pediatric patient cohort. Methods: Retrospective observational cohort study. Consecutive patients aged 0.01–17.9 years at evaluation between 1997–2023 for thyroid nodules larger than 0.5 cm recruited at the endocrinology department of Necker Children's University hospital in Paris, France, were included. The main outcome measures concerned the benign or malignant nature of the nodules. The diagnostic accuracy of fine‐needle aspiration biopsy (FNAB) was assessed, as well as the treatments used. Results: We studied 153 patients, 112 (73%) of them were female. Mean age at diagnosis was 12.6 years (0.01–17.9). Malignant nodules were identified more rapidly (0.65 years) than benign (1.25 years) lesions ( p = 0.03). The overall malignancy rate was 17% (26/153). Median largest nodule diameter was 13.1 (8–27) mm; diameter was < 10 mm for 23% of malignant nodules. FNAB was performed in 82/153 cases (53.6%) and was associated with larger nodule size ( p < 0.001) and history of radiation exposure. Autoimmune thyroiditis was present in 19% (4/21) of malignant nodules. By univariate analysis, significant predictors of malignancy were radiation exposure ( p = 0.032), calcifications ( p = 0.022), and lymph node involvement ( p = 0.019). None of these variables was substantial by multivariate analysis. Conclusion: Nodule size, ultrasound characteristics, and FNAB findings alone were insufficient to reliably detect malignancy. Increased vigilance is warranted for subcentimeter nodules and those with autoimmune thyroiditis. Close long‐term follow‐up is advised even in cases with benign cytology.

  • Open Access

    Approach to the patient: genetics and management of congenital hypothyroidism

    by Adrien Nguyen Quoc, Dulanjalee Kariyawasam, Michel Polak, Aurore Carré, Athanasia Stoupa

    Congenital hypothyroidism (CH) encompasses a diverse spectrum of disorders with diverse genetic etiologies and variable clinical courses, ranging from transient neonatal hyperthyrotropinemia to permanent thyroid hormone or thyrotropin deficiency. Advances in molecular genetics have substantially expanded the catalog of genes implicated in CH; however, the translation of this knowledge into everyday clinical practice remains challenging. In this Approach to the Patient, we use selected clinical vignettes to illustrate how genetic information can substantiate the diagnosis, management, and counseling of patients with CH. Rather than providing an exhaustive genetic review, this paper focuses on clinically relevant scenarios and pragmatic decision points—when to perform genetic testing, how results influence treatment duration and intensity, and how they guide prognostication and family counseling. This case-based framework emphasizes a pragmatic, patient-centered approach to the use of genetics in the management of CH.


  • New molecular insights in pathogenesis of congenital hypothyroidism

    by Athanasia Stoupa

    Nouvelles perspectives moléculaires dans la pathogenèse de l'hypothyroïdie congénitale: L'hypothyroïdie congénitale (HC) est la maladie endocrinienne néonatale la plus fréquente, affectant environ 1/3000 naissances et la cause réversible la plus commune de retard de développement. L'HC peut être primaire (due aux anomalies de développement ou de la fonction de la glande thyroïde) ou centrale (due aux anomalies de l'axe hypothalamo-hypophysaire). L'hypothyroïdie primaire est le plus souvent due à un défaut de développement thyroïdien (dysgénésie thyroïdienne, DT) ou un défaut de l'hormonosynthèse (dyshormonogènese). La DT est responsable pour environ 65% des HC, néanmoins une cause moléculaire est retrouvée chez <5% des patients. L'objectif de la thèse est d'identifier de nouveaux gènes responsables pour l'HC et comprendre les mécanismes moléculaires de l'hypothyroïdie. Nous avons utilisé des techniques de séquençage à haut débit par une approche par séquençage de l'exome (whole exome sequencing, WES) dans des familles consanguines avec plusieurs membres atteintes d'HC. Nous avons identifié un nouveau gène, TUBB1 qui encode pour la beta-tubuline1. Les patients mutés ont une DT et des anomalies du volume et de la fonction plaquettaires. Par le panel des gènes HypothySeq NGS développé au sein de notre équipe, nous avons pu élargir le phénotype thyroïdien connu jusqu'à présent pour les gènes impliqués dans l'hormonosynthèse thyroïdienne, TPO et NIS. Nous avons identifié une nouvelle mutation dans un gène récemment publié, appelé TANGO2 et avons étudié le mécanisme responsable pour l'hypothyroïdie chez les patients avec mutations bi alléliques de TANGO2. Au total, ce travail vise à élargir les connaissances actuelles sur l'origine moléculaire et les mécanismes responsables pour l'hypothyroïdie, et par conséquence, ouvrir des nouvelles perspectives sur la compréhension de la fonction thyroïdienne et le développement des nouvelles thérapies.

  • Open Access

    Thyrotoxicosis in MCT8 deficiency

    by Kristien Boelaert, Andrew Bauer, Anne R Cappola, Krishna Chatterjee, Johannes W Dietrich, Lindsey Nicol, Luca Persani, Salman Razvi, Athanasia Stoupa

    Monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan–Herndon–Dudley syndrome, is a rare, severely debilitating, and life-limiting genetic disorder caused by variants in the SLC16A2 gene that render the MCT8 thyroid hormone transporter partially or completely dysfunctional. MCT8 is highly expressed throughout the body, including the brain. Its deficiency disrupts thyroid hormone homeostasis and is associated with 2 distinct concomitant clinical presentations: persistent peripheral thyrotoxicosis resulting from elevated serum levels of triiodothyronine and neurodevelopmental impairment arising from low thyroid hormone levels in the brain. The disorder severely impacts quality of life and reduces life expectancy to a median of 35 years due to a range of clinical sequelae, with approximately 30% of affected individuals dying during childhood. Recognition and treatment of thyrotoxicosis are crucial to prevent associated symptoms and long-term sequelae.

  • Open Access

    EndoCompass Project: Research Roadmap for Thyroid Endocrinology

    by Agnieszka Piekielko-Witkowska, Rossella Elisei, Juliane Léger, Bela Bendlova, Barbora Bulanová Pekova, Philippe Caron, Cosimo Durante, Martin Fassnacht, Ulla Feldt-Rasmussen, Helena Filipsson Nyström, et al.

    Background: Endocrine science remains underrepresented in European Union research programs despite the fundamental role of hormone health in human well-being. Analysis of the CORDIS database reveals a persistent gap between the societal impact of endocrine disorders and their research prioritization. At national funding level, endocrine societies report limited or little attention of national research funding toward endocrinology. The EndoCompass project – a joint initiative between the European Society of Endocrinology and the European Society of Paediatric Endocrinology, aimed to identify and promote strategic research priorities in endocrine science to address critical hormone-related health challenges. Methods: Research priorities were established through comprehensive analysis of the EU CORDIS database covering the Horizon 2020 framework period (2014-2020). Expert consultation in thyroid endocrinology was conducted to identify key research priorities, followed by broader stakeholder engagement including society members and patient advocacy groups. Results: For thyroid disorders, research priorities encompass neoplastic and nonneoplastic conditions, focusing on disease mechanisms, improved diagnostics and treatments, and the impact of environmental and metabolic factors. Key areas include personalized medicine approaches, artificial intelligence applications, and the establishment of pan-European registries to advance understanding of rare thyroid conditions. Conclusions: The thyroid component of the EndoCompass project provides an evidence-based roadmap for strategic research investment. This framework identifies crucial investigation areas into thyroid disease pathophysiology, prevention, and treatment strategies, ultimately aimed at reducing the burden of thyroid disorders on individuals and society. The findings support the broader EndoCompass objective of aligning research funding with areas of highest potential impact in endocrine health.


  • Open Access

    From stem cells to organoids in thyroid: Useful tools or a step for cell therapy?

    by Dulanjalee Kariyawasam, Athanasia Stoupa, Adrien Nguyen Quoc, Ines Pimentel Dantas, Michel Polak, Aurore Carré


  • Open Access

    50 YEARS OF NEWBORN SCREENING FOR CONGENITAL HYPOTHYROIDISM: EVOLUTION OF INSIGHTS IN ETIOLOGY, DIAGNOSIS AND MANAGEMENT: Management during pregnancy and long-term outcomes of adult patients with congenital hypothyroidism

    by Charles Mégier, Dominique Luton, Athanasia Stoupa

    Congenital hypothyroidism (CH) is a lifelong condition, diagnosed shortly after birth through newborn screening in one-third of countries worldwide. When diagnosed and treated early in nonsyndromic CH, most patients exhibit similar fertility, metabolic and cardiovascular health, bone health, and quality of life compared to unaffected individuals. Special precautions are required for adult female patients with CH during pregnancy to ensure optimal management and to prevent serious maternal and fetal complications. In this review, we summarize the current knowledge on comorbidities and the long-term management of adults with CH, with a particular focus on pregnancy.


  • Non malignant ACTH-Independent Cushing Syndrome in Pediatric Patients: A Retrospective Observational Cohort Study

    by Myriam Hassan, Dinane Samara-Boustani, Alix Besançon, Anya Rothenbuhler, Caroline Storey, Graziella Pinto, Athanasia Stoupa, Marc Nicolino, Laura Gabriela González-Briceño, Adrien Nguyen Quoc, et al.

    Purpose: ACTH-independent Cushing’s syndrome (CS) is a rare cause of pediatric CS. Our objective was to describe the features of pediatric ACTH-independent CS and to compare groups defined by etiology. Methods: We conducted a retrospective observational study of patients aged 0–18 years at diagnosis between 1992–2022 for ACTH-independent CS in three Paris pediatric hospitals. Additionally, we compared the outcomes of McCune-Albright syndrome (MCAS) patients with CS and without CS. Results: Of the 15 patients with CS, seven had MCAS, seven primary pigmented nodular adrenocortical disease (PPNAD) as part of CNC (Carney complex), and one had CS with no etiology found. Age at CS diagnosis was 0,3 year old (0,17;1) in MCAS and 9 years old (5;15) in PPNAD. The MCAS group had more impaired growth retardation (-4,75 SDS in MCAS vs -1 SDS in CNC, p = 0,006) and higher prevalences of intrauterine growth retardation (P=0.01) and liver dysfunction at diagnosis (P=0.04). All seven MCAS patients had learning disabilities vs. only two CNC patients. 12 out of 15 had bilateral adrenalectomy. None of the MCAS patients received Growth hormone therapy, while 4 CNC patients benefited from growth hormon therapy. At end of follow up, growth recovered in both groups, albeit less in the MCAS group (-1,5 SDS in MCAS vs -0,5 SDS in CNC), in which liver dysfunction often persisted. Conclusions: ACTH-independent CS is rare but can lead to significant burden in children. Early diagnosis and management are essential. New drugs targeting adrenal steroid synthesis are awaited.


  • Open Access

    Genetics of primary congenital hypothyroidism: three decades of discoveries and persisting etiological challenges

    by Athanasia Stoupa, Aurore Carré, Michel Polak, Gabor Szinnai, Nadia Schoenmakers

    Primary congenital hypothyroidism (CH) is the most common neonatal endocrine disorder, and may be etiologically subdivided into thyroid dysgenesis, referring to abnormal thyroid development, and dyshormonogenesis, where a defective thyroid hormone biosynthesis pathway results in inadequate hormone production despite a structurally intact gland. Delayed treatment of neonatal hypothyroidism may result in irreversible neurodevelopmental impairment; therefore, where available, CH screening programs facilitate prompt diagnosis. However, the molecular basis for CH remains unclear in most of the cases. This review summarizes current understanding of the genetic etiologies underlying primary CH and associated phenotypes. Classical genetic causes are discussed in the context of their role in normal thyroid physiology. Genes recently reported to play a role in the pathogenesis of CH are discussed, and novel genomic mechanisms in CH are described.